GeneDx Reveals It Collects Just 32% on Genome Tests, Setting Up a Potential Doubling of Revenue Per Test by 2027
Q2 2026 earnings call, August 3, 2026
GeneDx used its second-quarter call to make an unusually candid disclosure: the company is only collecting payment on roughly 32% of its outpatient genome claims, well below what management considers a mature diagnostic reimbursement rate of 70%. The admission, paired with granular detail on why that gap exists and how it plans to close it, reframes the investment case around a reimbursement catch-up trade rather than a pure volume growth story.
CFO Kevin Feeley was explicit about the math. "If we were to double that 32% collection rate, what are zeros in our blended ARR today become paid units, driving revenue uplift that falls directly to the bottom line," he said. The company disclosed that exome collection rates, previously assumed by investors to be running near 55%, are actually comparable to genome once NICU volume—which collects at 100%—is stripped out. That is a meaningfully lower embedded reimbursement base than the Street likely had modeled, but it also frames a much larger runway than previously communicated.
Carelon Coverage Jump Won't Hit Revenue Until 2027
The quarter's most eye-catching data point was a policy shift from Carelon that expanded commercial genome coverage from 47% to 87% of lives in a single quarter, adding roughly 56 million covered lives. Management was careful to temper near-term expectations. "Coverage leads and payment lags," CEO Katherine Stueland said, noting that payers "don't always operationalize everything immediately." Feeley confirmed the guidance assumes no benefit in the third quarter, some contribution in the fourth quarter, and the bulk of the uplift arriving in 2027 given the trailing-period nature of GeneDx's revenue recognition.
A similar dynamic is playing out in Medi-Cal, where California published a new genome fee-for-service rate effective July 1. Feeley said the company is "monitoring adjudication experience closely" to confirm managed care organizations in the state are actually following the new fee schedule, rather than assuming the policy translates automatically into cash.
New President Lays Out a Four-Lever RCM Playbook
Mark Gardner, who joined as President six weeks before the call, used his first appearance to diagnose what he sees as the company's core operational gap: revenue cycle management has not kept pace with clinical demand. He outlined four levers—mix management, payer coverage expansion, payer-specific workflows, and AI-driven billing technology—as the mechanism to lift blended reimbursement. "We are underearning today on both exome and genome testing, and this is a significant opportunity that the whole of our company has rallied around," Gardner said. Notably, he flagged that payer-specific documentation and prior authorization requirements vary widely and that building compliant workflows is "a very attention and detail-oriented process," suggesting the fix is more operational grind than technology breakthrough, at least in the near term.
Deliberate Mix Shift Back Toward Exome Is Suppressing Reported ARR
Genome represented 32% of insurance-based outpatient volume mix in the second quarter, down from close to 40% in the first quarter, with the shift continuing into July. Management characterized this as intentional: by routing more volume through exome and its "reflex" upgrade pathway rather than whole genome, GeneDx buys time to build collection infrastructure before genome becomes the dominant product. The strategy shows up in the numbers as a headwind—blended average reimbursement rate was $3,258 per test in the quarter, roughly flat with the prior quarter despite improved mix, because exome collection rates were also flat. Management expects genome mix to settle around 30% or slightly lower in the second half of the year.
Financial Results and Capital Position
Total revenue came in at $114.4 million, up 11% year-over-year, with exome and genome revenue of $100.3 million, up 17%, on record volume of 30,785 tests, up 32%. Gross margin was 70%, up from 69% in the first quarter. The company returned to profitability a quarter earlier than previously guided, posting adjusted net income of $0.4 million, an $8.6 million sequential improvement. Full-year guidance was reaffirmed at $475 million to $490 million in revenue, with third-quarter revenue guided to $122 million to $124 million and adjusted net income of approximately $2 million.
Subsequent to quarter close, GeneDx expanded its debt facility by $50 million and received an equity investment from Blackstone Life Sciences, bringing pro forma liquidity to approximately $188 million. Management framed the capital raise as opportunistic rather than necessity-driven, saying it extends runway "well beyond sustained positive cash flow" while preserving flexibility for strategic investment. Feeley indicated third-quarter cash burn of roughly $10 million before a return to cash generation in the fourth quarter, with 2027 expected to bring sustained positive cash flow as cost cuts, RCM improvements, and volume-driven COGS leverage compound together.
Market Position and Emerging Channels
GeneDx said it retains approximately 80% market share among geneticists and has grown share among pediatric neurologists to roughly 50%. Early traction in general pediatrics—a channel opened following updated AAP guidelines—showed the highest growth rate on record in the quarter, though off a small base. Gardner noted that corporatized pediatric practices represent a particular opportunity to "aggregate demand and set policy for the larger corporate entity." A new ordering tool aimed at streamlining test requests for less experienced ordering physicians, dubbed one-minute ordering, is rolling out through the summer.
On competition, Gardner argued that GeneDx's proprietary Infinity variant database remains a structural moat, tying customer loyalty to diagnostic yield rather than price. Stueland struck a notably relaxed tone about rivals entering the genome testing market, arguing that more competitors "helps shape payer policy faster" and accelerates market development that benefits GeneDx's own coverage push.